Results 111 to 120 of about 11,641 (246)

Intravital Multiphoton Microscopy with Fluorescent Bile Salts in Rats as an In Vivo Biomarker for Hepatobiliary Transport Inhibition [PDF]

, 2018
The bile salt export pump (BSEP) is expressed at the canalicular domain of hepatocytes, where it mediates the elimination of monovalent bile salts into the bile.
Chen, Yuan, Dunn, Kenneth W., Dunn, Robert T., Morgan, Ryan E., Ryan, Jennifer, Volak, Laurie P.   +5 more
core   +1 more source

Discovery of Potential GPRC5D Inhibitors through Virtual Screening and Molecular Dynamics Simulations

ChemistryOpen, EarlyView.
A systematic computational workflow integrates Protein–Ligand Affinity prediction NETwork (PLANET), a GPU‐accelerated version of AutoDock Vina (Vina‐GPU), molecular mechanics/generalized born surface area (MM/GBSA), absorption distribution metabolism excretion toxicity prediction (admetSAR 3.0), molecular dynamics (MD), and absolute binding free energy
Xi Chen, Xinle Yang, Roufen Chen, Lei Xu, Xiaowu Dong, Zhen Cai   +5 more
wiley   +1 more source

Drug induced liver injury in HIV patients on dolutegravir based antiretroviral therapy regimens in Wolaita Sodo comprehensive specialized hospital

Scientific Reports
Drug induced liver injury is the most common and life-threatening condition associated with antiretroviral therapy. Dolutegravir (DTG) based combination antiretroviral therapy (ART) is currently first line treatment for HIV infected patients in Ethiopia.
Firew Abraham, Alemayehu Toma, Tamrat Balcha, Bereket Molla Tigabu   +3 more
doaj   +1 more source

Clinical and Genetic Associations in Cephalosporin‐Induced Liver Injury: Insights From the Drug‐Induced Liver Injury Network

Alimentary Pharmacology &Therapeutics, EarlyView.
Cephalosporin‐induced liver injury usually presents as a self‐limited, mixed, or cholestatic hepatitis without hypersensitivity features, typically developing 1 to 4 weeks after treatment. With cefazolin, it often occurs after a single parenteral dose. A strong genetic association has been found with HLA‐A*02:01, with more severe liver injury at onset.
Raj Vuppalanchi, Yi‐Ju Li, Don C. Rockey, Dina Halegoua‐DeMarzio, Robert J. Fontana, Herbert L. Bonkovsky, Christopher Koh, Joseph Odin, Huiman Barnhart, Jay H. Hoofnagle, Drug‐Induced Liver Injury Network (DILIN)   +10 more
wiley   +1 more source

A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. [PDF]

, 2019
Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast ...
Chien, A Jo, Esserman, Laura J, Hyland, Colby, Piawah, Sorbarikor, Rugo, Hope S, Umetsu, Sarah E   +5 more
core  

Diagnostics and outcome predictorso drug induced liver injury: a single center prospective study [PDF]

, 2022
Background: Although drug-induced liver injury (DILI) is a rare clinical event, it carries significant morbidity and mortality. The diagnostic approach of DILI is still challenging because of lack of reliable markers that would allow distinguishing DILI ...
Alhaddad, Omkolsoum M., Elsabaawy, Maha M., ElSharkawy, Amany S., Hendy, Olfat M., Mazaly, Mohamed A., Sabry, Aliaa A.   +5 more
core   +1 more source

Identification and Characterization of Three Novel Biomarkers for Mixed/Cholestatic Drug‐Induced Liver Injury

Hepatology Research, EarlyView.
Three metabolites, pyroglutamylglycine (pyroGluGly), phenylalanine (Phe), and phenylalanyltryptophan (PheTrp), were identified as candidate DILI biomarkers. The serum concentrations of pyroGluGly, Phe, and PheTrp demonstrated a high differentiating ability in patients with mixed and cholestatic DILI compared with those in patients who recovered from ...
Kosuke Saito, Tatehiro Kagawa, Keiji Tsuji, Yuji Kumagai, Ken Sato, Shotaro Sakisaka, Naoya Sakamoto, Mitsuhiko Aiso, Shunji Hirose, Nami Mori, Toshio Uraoka, Kazuhide Takata, Koji Ogawa, Kazuhiko Mori, Motonobu Sato, Takayoshi Nishiya, Kazuhiko Takamatsu, Noriaki Arakawa, Takashi Izumi, Ruri Kikura‐Hanajiri, Yasuo Ohno, Yoshiro Saito, Hajime Takikawa   +22 more
wiley   +1 more source

Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man [PDF]

, 2016
The current test systems employed by pharmaceutical industry are poorly predictive for drug-induced liver injury (DILI). The ‘MIP-DILI’ project addresses this situation by the development of innovative preclinical test systems which are both mechanism ...
Dragovic, Sanja, Gerets, Helga H, Hewitt, Philip G, Ingelman-Sundberg, Magnus, Juhila, Satu, Park, B Kevin, Snoeys, Jan, Vermeulen, Nico PE, Weaver, Richard J   +8 more
core   +1 more source

Development of Prediction Models for Drug-Induced Cholestasis, Cirrhosis, Hepatitis, and Steatosis Based on Drug and Drug Metabolite Structures

Frontiers in Pharmacology, 2020
Drug-induced liver injury (DILI) is one of the major reasons for termination of drug development. Due to the importance of predicting DILI in early phases of drug development, diverse in silico models have been developed to filter out DILI-causing ...
Hyun Kil Shin, Myung-Gyun Kang, Daeui Park, Daeui Park, Tamina Park, Tamina Park, Seokjoo Yoon, Seokjoo Yoon   +7 more
doaj   +1 more source

Genetic Connection to Drug-Induced Liver Injury (DILI) Through Statistical Learning Methods [PDF]

, 2021
R. E. Moore, Kristin McEuen
openalex   +1 more source